Payer incentives favouring lower cost outpatient and home care settings, combined with ergonomic design improvements that have substantially reduced the complexity of self-administration, are expanding the eligible patient population for home injection programs across diabetes, rheumatology, and oncology indications
However, to benefit from this treatment, its imperative to be mindful of dietary choices
Studies have also shown that individuals can lose an average of 12-15% of their initial body weight after 6 months of treatment
Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US With an updated formulation of semaglutide tablets and new branding, Ozempic will be available in a pill Ozempic (semaglutide) pill is the only oral GLP-1 medicine approved for both primary and secondary cardiovascular risk reduction of heart attack, stroke, and death in adults with type 2 diabetes at high risk for these events, including those with known heart disease1 Ozempic pill will be covered by insurance for most patients with type 2 diabetes for as little as $25 and available via self-pay through NovoCare Pharmacy and major telehealth providers PLAINSBORO, N.J., May 1, 2026 /PRNewswire/ -- Novo Nordisk announced that starting Monday, May 4, Ozempic (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US
